Life sciences company Azenta (NASDAQ:AZTA) reported Q4 CY2025 results topping the market’s revenue expectations, but sales ...

New England Biolabs (NEB ®) will present several scientific posters at this week's Society for Laboratory Automation and ...

Asian carp are large, voracious, and invasive. After their introduction to the United States during the early 1970s to ...

Twist Bioscience Corporation (NASDAQ:TWST) Q1 2026 Earnings Call Transcript February 2, 2026 Twist Bioscience Corporation ...

QIAsprint Connect marks entry into high-throughput sample processing, enabling labs to scale workflows with flexible ...

The Colossal BioVault and World Preservation Lab is a nine-figure initiative in the UAE. In addition, the UAE led an initial ...

Mass spectrometry (MS) has long been a cornerstone of chemical and biological analysis, but in biotech and biomanufacturing, it is now experiencing a renaissance. As drug modalities diversify—peptides ...

The biopharmaceutical sector is transitioning from reactive off-line quality control to a proactive quality by design (QbD) framework. Process analytical technology (PAT) enables this shift through ...

As America takes an axe to its health data, expanding wastewater surveillance could save lives ...

Financially, Azenta maintains a robust position. The company holds $571 million in cash and marketable securities and carries no debt, providing substantial flexibility for future strategic ...

The Midwest Creation Fellowship presents Dr. Paul Nelson from Logos Research Associates and Biola University on Feb. 9.

Detailed price information for Twist Bioscience Corp (TWST-Q) from The Globe and Mail including charting and trades.